Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07489573
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Hidradenitis Suppurativa (HS)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab — DRUG
    secukinumab 300 mg s.c. administered Q2W or Q4W

Study Details

This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe hidradenitis suppurativa (HS).

Key Dates

Start date
Jun 1, 2026
Status verified
Jun 2026
Primary completion
Sep 25, 2029
Completion
Nov 5, 2029

Study Design

Enrollment
36 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Secukinumab Q2W
    Participants receive secukinumab administered every two weeks (Q2W) at the specified dose
  • Experimental: Secukinumab Q4W
    Participants receive secukinumab administered every four weeks (Q4W) at the specified dose

Primary Outcome Measure

Percentage of participants achieving HiSCR50 at Week 16 [ Time Frame: Week 16 ]

Central Contacts

  • Novartis Pharmaceuticals
    +1-888-669-6682
    [email protected]
  • Novartis Pharmaceuticals
    +41613241111

Related Studies